Is Scribe Therapeutics Inc. (SCTX) Overvalued?
We dive into why Scribe Therapeutics Inc. (SCTX) could be considered overvalued on 2026-11-16, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Jenna Brashear
Tudor Pop
Rosalio Madrigal
Jenna Brashear
| Share Statistics | SCTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $299.4 | $208.2 | 33% |
|
| Shares Out (Mil) | 14.5 | 55.4 | 26% |
|
| Institutional Ownership | 69.4% | 92.9% | 42% |
|
| Float (Mil) | 6.4 | 40.7 | 15% |
|
| Beta | na | 1.00 | na |
|
| Avg Daily Volume (000s) | 322 | 570 | 50% |
|
| Price Change (52-week) |
na | 40.7% | na |
|
| Growth | SCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.3%) | na |
|
| EPS (5yr) | na | 15.5% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 1 | 3 | |
| Current EPS | ($0.285) | ($2.250) | ($3.387) | |
| Month Ago EPS | ($1.060) | ($5.590) | ($3.617) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | ($0.983) | ($5.925) | ($3.443) | |
| Year/Year Chg | (58.1%) | (74.9%) | (53.5%) | |
| Financials | SCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $15 | $39 | 11% |
|
| Net Income (TTM) (Mil) | ($44) | ($44) | 17% |
|
| EPS (TTM) | ($7.932) | ($1.400) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($38) | ($34) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $153 | $-0 | 81% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $4 | 23% |
|
| Enterprise Value (Q1) (Mil) | $141 | $138 | 24% |
|
| Valuation | SCTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.39 | 1.96 | 62% |
|
| P/E | na | 17.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | SCTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (202.8%) | 67.9% | 1% |
|
| Net Margin | (294.4%) | (50.8%) | 4% |
|
| ROA | (46.4%) | (47.4%) | 12% |
|
| ROE | (69.7%) | (51.6%) | 12% |
|
| Liabilities to Assets | 33.4% | 29.7% | 24% |
|
| F-Score | 1 | 3 | na |
|
Scribe Therapeutics Inc. did not pass any screens on 11/17/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors